{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:iclusig:0:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Aiclusig%3A0%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.001943, "timestamp_received": "2026-10-16T22:58:44.861665+00:00Z", "timestamp_returned": "2026-10-16T22:58:44.863608+00:00Z", "trace_id": "d4615c1e-6fa4-45d9-a6cd-8f9cd4edcb50" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:iclusig:0:0", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2013-07-01:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2013-07-01", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:iclusig", "type": "Document", "documentType": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "title": null, "aliases": [], "description": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised March 2026. Accessed August 2, 2026.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Incyte Biosciences Distribution B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Iclusig", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ponatinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2013-07-11", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-07-31", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:363", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C3174", "conceptType": "Disease", "name": "Chronic Myeloid Leukemia, BCR-ABL1+", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:CMLBCRABL1", "code": "CMLBCRABL1", "name": "Chronic Myeloid Leukemia, BCR-ABL1+", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Chronic+Myeloid+Leukemia%2C+BCR-ABL1%2B+%28CMLBCRABL1%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C3174", "code": "C3174", "name": "Chronic Myeloid Leukemia, BCR-ABL1 Positive", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3174" ] } }, "objectTherapeutic": { "id": "tx:ncit:C95777", "conceptType": "Therapy", "name": "Ponatinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1364347", "code": "1364347", "name": "ponatinib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1364347" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43013182", "code": "43013182", "name": "ponatinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43013182" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "BCR-ABL inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C95777", "code": "C95777", "name": "Ponatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:32", "present": true, "subject": { "id": "bmkr:32", "type": "CategoricalVariant", "name": "ABL1 p.T315I", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "type": "Allele", "name": "NP_005148.2:p.Thr315Ile", "aliases": [ "NP_005148.2:p.T315I", "ABL1 p.T315I" ], "description": "VRS variation of NP_005148.2:p.Thr315Ile", "digest": "D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "expressions": [ { "syntax": "hgvs.p", "value": "NP_005148.2:p.Thr315Ile", "extensions": [ { "name": "hgvs.p_short", "value": "p.T315I" } ] } ], "location": { "id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 315 of the Refseq protein NP_005148.2, which is the protein product of the MANE Select coding transcript for ABL1 (refseq:NM_005157.6).", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": { "id": "ga4gh:SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg", "type": "SequenceReference", "name": "NP_005148.2", "aliases": [ "ensembl:ENSP00000323315.5", "ga4gh:SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg", "refseq:NP_005148.2" ], "description": "The protein product of the MANE Select coding transcript for ABL1 (refseq:NM_005157.6), corresponding to the Refseq protein accession NP_005148.2.", "moleculeType": "protein", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg", "residueAlphabet": "aa" }, "start": 314, "end": 315, "sequence": "T" }, "state": { "type": "LiteralSequenceExpression", "sequence": "I" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:76", "conceptType": "Gene", "name": "ABL1", "primaryCoding": { "id": "coding:hgnc:76", "code": "HGNC:76", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000097007", "code": "ENSG00000097007", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000097007" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:25", "code": "25", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/25" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005157.6", "code": "NM_005157.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "9" }, { "name": "start_position", "value": 133748283 }, { "name": "end_position", "value": 133748283 }, { "name": "reference_allele", "value": "C" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.944C>T" }, { "name": "protein_change", "value": "p.T315I" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 5 }, { "name": "rsid", "value": "rs121913459" }, { "name": "hgvsg", "value": "9:g.133748283C>T" }, { "name": "hgvsc", "value": "ENST00000318560.5:c.944C>T" } ] } }, { "id": "bmkr.criterion:12", "present": true, "subject": { "id": "bmkr:12", "type": "CategoricalVariant", "name": "BCR::ABL1", "constraints": [ { "type": "AdjacencyConstraint", "orderKnown": true, "adjoinedElements": [ { "id": "gene:hgnc:1014", "conceptType": "Gene", "name": "BCR", "primaryCoding": { "id": "coding:hgnc:1014", "code": "HGNC:1014", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000186716", "code": "ENSG00000186716", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000186716" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:613", "code": "613", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/613" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004327.4", "code": "NM_004327.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4" ] } } ] }, { "id": "gene:hgnc:76", "conceptType": "Gene", "name": "ABL1", "primaryCoding": { "id": "coding:hgnc:76", "code": "HGNC:76", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000097007", "code": "ENSG00000097007", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000097007" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:25", "code": "25", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/25" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005157.6", "code": "NM_005157.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6" ] } } ] } ] } ], "extensions": [ { "name": "biomarker_type", "value": "Gene fusion" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:iclusig:0", "type": "Indication", "description": "Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2013-07-01:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2013-07-01", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:iclusig", "type": "Document", "documentType": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "title": null, "aliases": [], "description": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised March 2026. Accessed August 2, 2026.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Incyte Biosciences Distribution B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Iclusig", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ponatinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2013-07-11", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-07-31", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }